Reuters Health Rounds: CGM for Type 2 Non-Insulin Users Broaden Dexcom's TAM

What happened

Reuters reports that continuous glucose monitoring devices benefit type 2 diabetes patients even those not on insulin, aligning with clinical evidence Dexcom has been leveraging to expand beyond its core insulin user base. The news directly supports Dexcom's strategic push into non-insulin type 2 and wellness segments, including its OTC Stelo product, which management identifies as a key growth pillar. This validation comes amid a backdrop where Dexcom's stock has been volatile due to GLP-1 fears, pricing pressure, and an open FDA warning letter, but recent financials show re-accelerated revenue growth at 22% year-over-year in Q3 2025. The article's implication that CGM improves outcomes for a broader diabetic population could reinforce payer willingness to cover Dexcom devices for non-insulin users, potentially expanding its addressable market. While not a company-specific catalyst, the news supports the thesis that CGM adoption will continue to grow beyond the insulin-dependent population, offsetting concerns about GLP-1 substitution.

Implication

Investors should view this external validation as supportive of Dexcom's growth narrative but not as a near-term earnings driver; the company still must execute on margin expansion and FDA remediation. The potential for broader reimbursement for CGM in non-insulin type 2 patients could accelerate sensor volume growth, particularly for Stelo and Dexcom ONE+, which would help sustain double-digit revenue growth. However, the stock's current valuation at ~38x PE already prices in some of this upside, and the risk of CMS competitive bidding and pricing pressure means that margin improvements are critical for re-rating. The FDA warning letter remains an unresolved overhang: any escalation could overshadow positive clinical news, so position sizing should remain measured. In the base case, if Dexcom delivers on 2026 guidance of 11-13% revenue growth and 63-64% gross margin, the stock could re-rate toward $80-90; this news nudges the probabilities slightly in favor of the bull scenario but does not change the foundational risks.

Thesis delta

The original thesis highlighted expansion into type 2/non-insulin as a key growth driver; this news provides additional external evidence supporting that expansion, slightly increasing confidence in the bull scenario. No change to the overall investment stance (potential buy with conviction 3.5), but the probability of the bull case (implied value $95) may tick up by 1-2 percentage points at the expense of the bear case, though regulatory and pricing risks still cap the re-rating potential. The thesis remains intact: buy at attractive entry below $65 with trim above $90, and monitor for FDA closure and CMS bidding outcomes.